UCB, in­vestors back a neu­ro­sciences start­up called Syn­de­si; Ger­many's Biofron­tera in­creas­es US IPO pric­ing range

→ UCB and a syn­di­cate of Bel­gian and in­ter­na­tion­al in­vestors have joined hands to launch a new biotech called Syn­de­si Ther­a­peu­tics. The Bel­gian start­up gained …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER